Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE55.6800
- TODAY'S CHANGE (%)0.1400 (0.2521%)
- Bid / Lots55.3400/ 1
- Ask / Lots56.1600/ 1
- Open / Previous Close55.7800 / 55.5400
- Day Range
- 52 Week Range
- Volume456,102
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 2627 | 55.35 |
| 09:35 ET | 100 | 55.315 |
| 09:37 ET | 1051 | 54.96 |
| 09:42 ET | 752 | 55.33 |
| 09:44 ET | 300 | 55.52 |
| 09:48 ET | 100 | 55.34 |
| 09:50 ET | 1725 | 55.68 |
| 09:51 ET | 6763 | 55.51 |
| 09:53 ET | 2400 | 55.56 |
| 09:55 ET | 300 | 55.5 |
| 09:57 ET | 800 | 55.51 |
| 10:00 ET | 714 | 55.545 |
| 10:02 ET | 3771 | 55.44 |
| 10:04 ET | 1505 | 55.6699 |
| 10:06 ET | 200 | 55.49 |
| 10:08 ET | 5157 | 55.405 |
| 10:09 ET | 824 | 55.44 |
| 10:11 ET | 400 | 55.37 |
| 10:13 ET | 300 | 55.365 |
| 10:15 ET | 1100 | 55.14 |
| 10:18 ET | 900 | 55.22 |
| 10:20 ET | 1100 | 55.205 |
| 10:22 ET | 200 | 54.98 |
| 10:27 ET | 6457 | 54.98 |
| 10:29 ET | 200 | 54.885 |
| 10:31 ET | 1745 | 55 |
| 10:33 ET | 900 | 54.86 |
| 10:36 ET | 200 | 54.905 |
| 10:38 ET | 100 | 54.885 |
| 10:40 ET | 2031 | 55.15 |
| 10:42 ET | 800 | 55.095 |
| 10:44 ET | 1200 | 55.155 |
| 10:45 ET | 1200 | 55.335 |
| 10:47 ET | 100 | 55.35 |
| 10:49 ET | 400 | 55.34 |
| 10:54 ET | 308 | 55.36 |
| 10:56 ET | 500 | 55.35 |
| 10:58 ET | 7500 | 55.355 |
| 11:00 ET | 2800 | 55.44 |
| 11:02 ET | 100 | 55.515 |
| 11:03 ET | 672 | 55.49 |
| 11:05 ET | 123 | 55.49 |
| 11:07 ET | 1499 | 55.625 |
| 11:12 ET | 200 | 55.615 |
| 11:14 ET | 1208 | 55.865 |
| 11:16 ET | 1381 | 55.79 |
| 11:18 ET | 700 | 55.82 |
| 11:21 ET | 100 | 55.73 |
| 11:23 ET | 1600 | 55.9004 |
| 11:25 ET | 200 | 56.02 |
| 11:27 ET | 379 | 55.945 |
| 11:30 ET | 1353 | 56.105 |
| 11:32 ET | 600 | 56.125 |
| 11:34 ET | 600 | 56.15 |
| 11:36 ET | 1100 | 56.14 |
| 11:38 ET | 200 | 56.14 |
| 11:39 ET | 1500 | 56.23 |
| 11:41 ET | 512 | 56.16 |
| 11:43 ET | 200 | 56.13 |
| 11:45 ET | 1500 | 56.135 |
| 11:48 ET | 100 | 56.15 |
| 11:50 ET | 1100 | 56.19 |
| 11:52 ET | 500 | 56.09 |
| 11:54 ET | 200 | 56.16 |
| 11:56 ET | 1677 | 56.235 |
| 12:01 ET | 855 | 56.21 |
| 12:03 ET | 300 | 56.14 |
| 12:06 ET | 200 | 56.14 |
| 12:08 ET | 100 | 56.21 |
| 12:10 ET | 2621 | 56.265 |
| 12:12 ET | 1550 | 56.48 |
| 12:14 ET | 584 | 56.38 |
| 12:15 ET | 600 | 56.56 |
| 12:17 ET | 1000 | 56.56 |
| 12:19 ET | 500 | 56.43 |
| 12:21 ET | 100 | 56.445 |
| 12:24 ET | 704 | 56.495 |
| 12:26 ET | 120 | 56.56 |
| 12:28 ET | 500 | 56.56 |
| 12:30 ET | 700 | 56.59 |
| 12:32 ET | 1205 | 56.42 |
| 12:33 ET | 1400 | 56.37 |
| 12:35 ET | 766 | 56.39 |
| 12:37 ET | 1020 | 56.335 |
| 12:39 ET | 1312 | 56.43 |
| 12:42 ET | 300 | 56.44 |
| 12:44 ET | 600 | 56.55 |
| 12:46 ET | 100 | 56.6 |
| 12:51 ET | 300 | 56.655 |
| 12:53 ET | 100 | 56.56 |
| 12:57 ET | 100 | 56.68 |
| 01:00 ET | 957 | 56.66 |
| 01:04 ET | 900 | 56.58 |
| 01:06 ET | 700 | 56.56 |
| 01:08 ET | 100 | 56.595 |
| 01:09 ET | 700 | 56.665 |
| 01:11 ET | 1440 | 56.72 |
| 01:13 ET | 367 | 56.74 |
| 01:15 ET | 100 | 56.78 |
| 01:20 ET | 700 | 56.74 |
| 01:22 ET | 100 | 56.705 |
| 01:24 ET | 1413 | 56.81 |
| 01:26 ET | 100 | 56.82 |
| 01:27 ET | 300 | 56.81 |
| 01:29 ET | 1100 | 56.75 |
| 01:33 ET | 1704 | 56.7 |
| 01:36 ET | 300 | 56.77 |
| 01:38 ET | 2508 | 56.76 |
| 01:40 ET | 1500 | 56.59 |
| 01:42 ET | 621 | 56.58 |
| 01:44 ET | 24320 | 55.945 |
| 01:45 ET | 3783 | 56.07 |
| 01:47 ET | 1047 | 56.27 |
| 01:49 ET | 1055 | 56.215 |
| 01:54 ET | 300 | 56.14 |
| 01:56 ET | 200 | 56.17 |
| 01:58 ET | 1300 | 56.18 |
| 02:00 ET | 1025 | 56.2525 |
| 02:02 ET | 100 | 56.29 |
| 02:03 ET | 500 | 56.23 |
| 02:07 ET | 2338 | 56.33 |
| 02:09 ET | 963 | 56.49 |
| 02:12 ET | 100 | 56.5 |
| 02:14 ET | 239 | 56.43 |
| 02:16 ET | 600 | 56.47 |
| 02:18 ET | 500 | 56.26 |
| 02:20 ET | 400 | 56.36 |
| 02:21 ET | 900 | 56.26 |
| 02:23 ET | 400 | 56.34 |
| 02:25 ET | 1507 | 56.265 |
| 02:27 ET | 700 | 56.45 |
| 02:30 ET | 243 | 56.385 |
| 02:32 ET | 747 | 56.45 |
| 02:34 ET | 300 | 56.41 |
| 02:36 ET | 500 | 56.425 |
| 02:38 ET | 200 | 56.48 |
| 02:39 ET | 1300 | 56.44 |
| 02:41 ET | 2869 | 56.385 |
| 02:43 ET | 600 | 56.29 |
| 02:45 ET | 1510 | 56.21 |
| 02:48 ET | 2100 | 56.14 |
| 02:52 ET | 2008 | 56.07 |
| 02:54 ET | 500 | 55.945 |
| 02:56 ET | 700 | 56.02 |
| 02:57 ET | 1853 | 56.02 |
| 02:59 ET | 700 | 55.95 |
| 03:01 ET | 1517 | 55.905 |
| 03:03 ET | 599 | 55.83 |
| 03:06 ET | 900 | 55.675 |
| 03:08 ET | 522 | 55.74 |
| 03:10 ET | 500 | 55.77 |
| 03:12 ET | 400 | 55.7 |
| 03:14 ET | 1000 | 55.72 |
| 03:15 ET | 1122 | 55.72 |
| 03:17 ET | 900 | 55.72 |
| 03:19 ET | 1000 | 55.8 |
| 03:21 ET | 996 | 55.79 |
| 03:24 ET | 1000 | 55.81 |
| 03:26 ET | 1000 | 55.815 |
| 03:28 ET | 900 | 55.815 |
| 03:30 ET | 1400 | 55.765 |
| 03:32 ET | 1176 | 55.81 |
| 03:33 ET | 2000 | 55.91 |
| 03:35 ET | 1000 | 55.89 |
| 03:37 ET | 2224 | 56.02 |
| 03:39 ET | 100 | 56.025 |
| 03:42 ET | 1500 | 56.035 |
| 03:44 ET | 3449 | 55.82 |
| 03:46 ET | 1500 | 55.715 |
| 03:48 ET | 4008 | 55.945 |
| 03:50 ET | 2700 | 55.88 |
| 03:51 ET | 3382 | 55.75 |
| 03:53 ET | 3810 | 55.97 |
| 03:55 ET | 3748 | 55.95 |
| 03:57 ET | 7782 | 55.805 |
| 04:00 ET | 78014 | 55.68 |
Nov 5, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 1, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
12:43PM ET on Friday Nov 01, 2024 by Dow JonesDJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
10:30AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
Agios Reports Business Highlights and Third Quarter 2024 Financial Results, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones*DJ Agios Pharmaceuticals 3Q EPS $16.22 >AGIO, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 3.2B | 4.5x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Verona Pharma PLC | 3.1B | -20.5x | --- |
Merus NV | 3.0B | -11.6x | --- |
Edgewise Therapeutics Inc | 3.0B | -21.6x | --- |
Dyne Therapeutics Inc | 3.0B | -8.3x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
|---|---|
Revenue (TTM) | $32.9M |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $12.28 |
Book Value | $14.50 |
P/E Ratio | 4.5x |
Price/Sales (TTM) | 96.4 |
Price/Cash Flow (TTM) | 4.3x |
Operating Margin | 2,075.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
